Close Menu

NEW YORK – UgenTec and DMark Biosciences have signed a distribution agreement to offer the UgenTec FastFinder PCR analysis software products to molecular diagnostics laboratories in Canada.

Toronto-based DMark specializes in providing workflow solutions to molecular biology and protein biology labs with an emphasis on qPCR and sequencing.

Duane Mendis, general manager at DMark, noted in a statement that Canada is currently undergoing a significant ramp up of SARS-CoV-2 PCR testing initiatives.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Centers for Disease Control and Prevention has identified a small group of breakthrough COVID-19 cases, the Wall Street Journal reports.

Vox and Nature discuss the importance of preparing for the next pandemic.

The New York Times reports that the US Department of Defense is to use genetic genealogy approaches to identify the remains of unknown soldiers.

In Nature this week: comparison of five circulating tumor DNA assays, resequencing analysis of lettuce gives insight into its domestication, and more.

Apr
29
Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

May
12
Sponsored by
Combinati

This webinar will discuss a recent study that characterized the relationships between SARS-CoV-2 RNAemia and disease severity, clinical deterioration, and extrapulmonary complications (EPCs).

May
18
Sponsored by
Bio-Rad

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.  

Jun
18
Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.